Development of a cell-based assay for monitoring hepatitis C virus NS3/4A protease activity

Acta Virologica

Volumn 52, Issue 3, 2008, Pages 133-141

  Lei, Y F ^c   Yin, W ^a   Yang, J ^a   Lv, X ^a   Wei, S H ^a   An, Q X ^b   Hu, X B ^a   Xu, Z K ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NONE

Author keywords

Apoptosis; Hepatitis C virus; MTT assay; NS3 4A protease; Recombinant Casp3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; POLYPROTEIN; PROTEINASE INHIBITOR; RECOMBINANT ENZYME;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MAMMAL CELL; MONITORING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SPECTROPHOTOMETRY;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; COLORIMETRY; HEPACIVIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TRANSFECTION; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

HEPATITIS C VIRUS; MAMMALIA;

EID: 54249150656     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Abrignani S, Houghton M, Hsu HH (1999): Perspectives for a vaccine against hepatitis C virus. J. Hepatol. 31, S259-263.
2. Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, Fujita T, Hiscott J, Meurs EF (2005): Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J. Virol. 79, 3969-3978.
3. Chen PJ, Wu HL, Wang CJ, Chia JH, Chen DS (1997): Molecular biology of hepatitis D virus: research and potential for application. J. Gastroenterol. Hepatol. 12, S188-S192.
4. Cho YG, Moon HS, Sung YC (1997): Construction of hepatitis CSIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity. J. Virol. Methods 65, 201-207.
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989): Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362.
6. Chung V, Carroll AR, Gray NM, Parry NR, Thommes PA, Viner KC, D'Souza EA(2005): Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors. Antimicrob. Agents Chemother. 49,1381-1390.
7. Clarke B (1997): Molecular virology of hepatitis C virus. J. Gen. Virol. 78, 2397-2410.
8. Cohen GM (1997): Caspases: the executioners of apoptosis. Biochem. J. 326, 1-16.
9. Cornberg M, Wedemeyer H, Manns MP (2002): Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr. Gastroenterol. Rep. 4, 23-30.
10. De Francesco R, Steinkuhler C (2000): Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr. Top. Microbiol Immunol. 242, 149-169.
11. Dimasi N, Pasquo A, Martin F, Di Marco S, Steinkuhler C, Cortese R, Sollazzo M (1998): Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein. Protein Eng. 11, 1257-1265.
12. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998): A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43-50.
13. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C (2005): Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42, 255-262.
14. Failla C, Tomei L, De Francesco R (1994): Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68, 3753-3760.
15. Failla C, Tomei L, De Francesco R (1995): An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J. Virol. 69, 1769-1777.
16. Farrell GC (2007): New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol. 22, 607-610.
17. Foy E, Li K, Sumpter R Jr, Loo Y M, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M Jr (2005): Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. USA 102, 2986-2991.
18. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr (2003): Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145-1148.
19. Hahm B, Han DS, Back SH, Song OK, Cho MJ, Kim CJ, Shimotohno K, Jang SK (1995): NS3-4A of hepatitis C virus is a chymotrypsin-like protease. J. Virol. 69, 2534-2539.
20. Hsu EC, Hsi B, Hirota-Tsuchihara M, Ruland J, Iorio C, Sarangi F, Diao J, Migliaccio G, Tyrrell DL, Kneteman N, Richardson CD (2003): Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat. Biotechnol. 21, 519-525.
21. Ingallinella P, Altamura S, Bianchi E, Taliani M, Ingenito R, Cortese R, De Francesco R, Steinkuhler C, Pessi A (1998): Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 37, 8906-8914.
22. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA (1996): Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355.
23. Kim SY, Park KW, Lee YJ, Back SH, Goo JH, Park OK, Jang SK, Park WJ (2000): In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis. Anal. Biochem. 284, 42-48.
24. Koch JO, Lohmann V, Herian U, Bartenschlager R (1996): In vitro studies on the activation of the hepatitis C virus NS3 proteinase by the NS4A cofactor. Virology 221, 54-66.
25. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M (2003): An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189.
26. Lee JC, Chang CF, Chi YH, Hwang DR, Hsu JT (2004): A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. J. Virol. Methods 116, 27-33.
27. Lee JC, Shih YF, Hsu SP, Chang TY, Chen LH, Hsu JT (2003): Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells. Anal. Biochem. 316, 162-170.
28. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM (2005): Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 102, 2992-2997.
29. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R (1999): Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
30. McHutchison JG (2002): Hepatitis C advances in antiviral therapy: what is accepted treatment now? J. Gastroenterol. Hepatol. 17, 431-441.
31. Memon MI, Memon MA (2002): Hepatitis C: an epidemiological review. J. Viral. Hepat. 9, 84-100.
32. Pasquo A, Nardi MC, Dimasi N, Tomei L, Steinkuhler C, Delmastro P, Tramontano A, De Francesco R (1998): Rational design and functional expression of a constitutively active single-chain NS4A-NS3 proteinase. Fold Des. 3, 433-441.
33. Purcell R (1997): The hepatitis C virus: overview. Hepatology 26, 11S-14S.
34. Reiser M, Hinrichsen H, Benhamou Y, Reesink HW, Wedemeyer H, Avendano C, Riba N, Yong CL, Nehmiz G, Steinmann GG (2005): Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41, 832-835.
35. Summa V (2005): VX-950 (Vertex/Mitsubishi). Curr. Opin. Investig. Drugs 6, 831-837.
36. Tanji Y, Hijikata M, Satoh S, Kaneko T, Shimotohno K (1995): Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J. Virol. 69, 1575-1581.
37. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF (1999): Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 5, 29-33.
38. Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, Kagi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, Senaldi G, Howard T, Lowe SW, Mak TW (1998): Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12, 806-819.
39. Zhang R, Durkin J, Windsor WT, McNemar C, Ramanathan L, Le HV (1997): Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J. Virol. 71, 6208-6013.